

NRG Oncology Scientific Session

Research Review Hosted by the Publications Committee

Friday, February 8, 2019
8:00-10:00 am

NRG Oncology February 2019 Semiannual Meeting
Phoenix Convention Center

NRG
ONCOLOGY

Advancing Research. Improving Lives.™

PRESENTATIONS



NRG Oncology Phase II Randomized Trial of nivolumab with or without Ipilimumab in patients with persistent or recurrent ovarian cancer.

Presenter: Robert Burger, MD
Discussant: Sarah Temkin, MD



Preservation of neurocognitive function (NCF) with hippocampal avoidance during whole-brain radiotherapy (WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001.

Presenter: Vinai Gondi, MD
Discussant: Paul Sperduto, MD



Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT Trial.

Presenter: Alan Pollack, MD
Discussant: William Hall, MD



Post-resection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: analysis of NRG Oncology RTOG trial 9704

Presenter: William Regine, MD
Discussant: Richard Tuli, MD



NRG-RTOG 1016: phase III trial comparing radiation/cetuximab to radiation/cisplatin in HPV-related cancer of the oropharynx.

Presenter: Andy Trotti, MD, PhD
Discussant: Stuart Wong, MD



Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer.

Presenter: Frank, Vicini, MD
Discussant: Atif Khan, MD

Register for the semiannual meeting on [the NRG Oncology website](#)